DRAUPNIR BIO
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.
DRAUPNIR BIO
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Risskov, Midtjylland, Denmark
Country:
Denmark
Website Url:
http://www.draupnir.bio
Total Employee:
10001+
Status:
Active
Total Funding:
33 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Amazon
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Lay Line Genomics S.p.A.
Lay Line Genomics S.p.A. is the straight line tracing the course following which a boat can fetch an upwind mark
MediGene
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Current Employees Featured
Founder
Investors List
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Venture Round - Draupnir Bio
Inkef
Inkef investment in Venture Round - Draupnir Bio
Novo Holdings
Novo Holdings investment in Venture Round - Draupnir Bio
Gilde Healthcare
Gilde Healthcare investment in Venture Round - Draupnir Bio
Official Site Inspections
http://www.draupnir.bio
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Draupnir Bio"
Draupnir Bio
Draupnir Bio is developing new innovative therapies for patients.See details»
Draupnir Bio • About
Draupnir Bio is a spin out company, from Aarhus University, Denmark and the Max-Planck Society, Germany. Backed by a syndicate of leading European investors – Gilde Healthcare …See details»
Draupnir Bio - Crunchbase Company Profile & Funding
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a …See details»
Draupnir Bio 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for Draupnir Bio. Use the PitchBook Platform to explore the full profile.See details»
Draupnir Bio
Draupnir Bio establishes Scientific Advisory Board of international experts in cholesterol metabolism and cardiovascular disease September 2021 4 min NewsSee details»
Draupnir Bio - Funding, Financials, Valuation & Investors
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.See details»
Draupnir Bio: One of Europe's top 10 most promising biotech stars …
Oct 23, 2024 Draupnir Bio was founded in 2017 by Simon Glerup, Peder Madsen and Camilla Gustafsen as a spinout company from Aarhus University. The company is now ranked in the …See details»
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round …
Draupnir Bio ApS. (7/1//24). "Press Release: Draupnir Bio Completes €12 Million Seed Round to Progress Development of Oral Small Molecule Degraders of Extracellular Proteins". …See details»
draupnir.bio - Aarhus University
Nov 5, 2024 Draupnir Bio has developed a platform for exploring the glycome to develop novel therapeutics. The platform is based on array technology, protein chemistry and advanced …See details»
Draupnir Bio | DANISH BIO – DANSK BIOTEK
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Targeted protein degradation is an …See details»
Draupnir Bio Company Profile - Office Locations, Competitors
See insights on Draupnir Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Draupnir Bio Secures €12 Million Seed Funding to Pioneer …
Copenhagen, Denmark – July 22, 2024 – Draupnir Bio, a Danish biotechnology company, has closed a €12 million seed funding round. The funds will be used to advance their development …See details»
Simon Glerup - BioLeader Interview - PIR International
Simon Glerup is CSO, co-founder and board member of Draupnir Bio, co-founder of Teitur Trophics, and co-founder of Muna Therapeutics.See details»
Draupnir Bio establishes Scientific Advisory Board of
Sep 23, 2021 Press Release Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen,...See details»
Draupnir Bio • Draupnir Bio completes €12 million seed round to ...
Jul 17, 2024 MP Healthcare and EIFO join existing investors, Gilde Healthcare Partners, Inkef Capital and Novo Holdings Copenhagen, Denmark, 17 July 2024 – Draupnir Bio (“Draupnir”), …See details»
€12 million raised for extracellular protein degradation research
Jul 19, 2024 Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD).See details»
Research programme: PCSK9 inhibitors - Draupnir Bio
Orally administered PCSK9 inhibitors (proprotein convertase subtilisin kexin type 9) are small molecule therapeutics, being developed by Draupnir Bio (spin-outSee details»
Draupnir Bio • Careers
Draupnir Bio is developing new innovative therapies for patients.See details»
Draupnir Bio-Draupnir Bio ApS-企业详情-InvestGO数据库-ByDrug …
查看医药魔方InvestGO®数据库Draupnir Bio的公司信息。Draupnir Bio（Draupnir Bio ApS），公司简介：Draupnir Bio was founded in 2017 as a spin-out from Aarhus University, Denmark, …See details»
Draupnir Bio • Research
At Draupnir, we are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, …See details»